Skye Bioscience, Inc. announced that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion did not meet its primary endpoint for lowering intraocular pressure, leading to the discontinuation of the clinical development of SBI-100 OE and the redirection of resources to its obesity program.